绝经后骨质疏松症女性使用阿巴洛肽的治疗模式:一项真实世界观察性研究
该研究回顾性收集美国六个学术与临床实践中173例新使用阿巴洛肽的绝经后骨质疏松症女性的病历,评估真实世界治疗模式。结果显示96.0%的患者至少有一次骨质疏松管理就诊,55.5%可及药物支持项目,64.8%按处方完成治疗,停药最常见原因为经济因素(31.2%)和耐受性(22.8%)。
要点
- 173例患者中96.0%至少一次骨质疏松管理就诊,55.5%可及药物支持项目。
- 中位治疗时长18.6个月,105/162(64.8%)按处方完成阿巴洛肽治疗。
- 停药最常见原因为经济因素(31.2%)和耐受性(22.8%)。
核心结论
- 多数患者按处方完成阿巴洛肽治疗,超过半数后续换用抗骨吸收药物。
- 作者认为这一良好治疗行为可能源于定期随访就诊以及药物和患者支持服务的可及性。
研究设计与样本
- 回顾性收集美国六个学术与临床实践中至少一次阿巴洛肽处方的患者数据。
- 共纳入173例患者,平均(标准差)年龄69.8(7.4)岁。
主要发现
- 开始阿巴洛肽治疗时,78.6%的患者曾接受其他骨质疏松药物治疗;距之前骨质疏松药物停用的平均(标准差)时间为1.7(3.2)年。
- 从阿巴洛肽起始日期起收集24个月随访数据的患者占94.0%,6.0%的患者有12-24个月随访数据。
- 随访期间,96.0%的患者至少有一次骨质疏松管理就诊,55.5%可及药物支持项目。
- 中位治疗时长18.6个月,105/162(64.8%)按处方完成阿巴洛肽治疗;停药最常见原因为经济因素(31.2%)和耐受性(22.8%)。
- 完成阿巴洛肽疗程后,82/162(50.6%)患者换用另一种骨质疏松药物,从疗程完成到启用后续药物的中位时间为21天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Review of medical records from 173 women with osteoporosis who received abaloparatide treatment revealed that 96.0% had at least one visit for osteoporosis management and 55.5% had medication support group access. The most common reasons for discontinuing treatment were financial (31.2%) and tolerability (22.8%). Most patients (64.8%) completed treatment as prescribed. PURPOSE: Abaloparatide is approved for the treatment of women with postmenopausal osteoporosis at high risk for fracture. This study evaluated real-world treatment patterns for patients new to abaloparatide, regardless of osteoporosis treatment history. METHODS: Data for patients with ≥ 1 prescription for abaloparatide were collected retrospectively from six academic and clinical practice settings across the US. RESULTS: A total of 173 patients were enrolled (mean [SD] age, 69.8 [7.4] years). At the time of abaloparatide treatment initiation, 78.6% had received other osteoporosis medications. Mean (SD) time from discontinuation of osteoporosis medications prior to initiation of abaloparatide was 1.7 (3.2) years. Twenty-four months of follow-up data from the initiation date of abaloparatide was collected from 94.0% of patients and 6.0% of patients had 12-24 months of follow-up. During the follow-up period, 96.0% of patients had at least one visit for osteoporosis management and 55.5% had access to a medication support program. The median duration of therapy was 18.6 months and 105/162 (64.8%) completed abaloparatide treatment as prescribed. The most common reasons for treatment discontinuation were financial (31.2%) and tolerability (22.8%). Following completion of a course of treatment with abaloparatide, 82/162 (50.6%) patients transitioned to another osteoporosis medication. The median time between abaloparatide treatment course completion and the initiation of follow-on medication was 21 days. CONCLUSION: Most patients completed treatment with abaloparatide as prescribed, and over half continued with an antiresorptive agent. This favorable conduct may be the result of regular follow-up visits and accessibility to both medication and patient support services.
引用
- Gold DT, Beckett T, Deal C, et al. Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study. Osteoporos Int. 2024. PMID: 38653862. doi:10.1007/s00198-024-07070-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。